Ocuphire Pharma has closed $5 million in financing to support multiple phase 2 trials of Nyxol, its lead drug candidate, according to a press release.
Nyxol, an ophthalmic solution eye drop containing phentolamine mesylate and designed to treat front-of-the-eye disorders, is being tested for night vision disturbances, glaucoma and reversal of mydriasis, while a fixed-dose combination of Nyxol is being explored to treat presbyopia.
“We are thrilled to have the support of our investors to advance Nyxol in clinical trials. As of mid-July, we are pleased to report that we (Read more...)
Uncategorized